FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome - Le, Robert Q.; Li, Liang; Yuan, Weishi; Shord, Stacy S.; Nie, Lei; Habtemariam, Bahru A.; Przepiorka, Donna; Farrell, Ann T.; Pazdur, Richard (The oncologist (Dayton, Ohio), 2018)
Keywords: Chimeric antigen receptor; Cytokine release syndrome; Immunotherapy; Interleukin‐6; Regulatory Issues: FDA; T cell; Tocilizumab; Cytokine release syndrome; Chimeric antigen receptor; Interleukin‐6; Tocilizumab; Immunotherapy; T cell